Ignite Creation Date:
2025-12-25 @ 3:01 AM
Ignite Modification Date:
2026-02-27 @ 1:09 AM
Study NCT ID:
NCT03683433
Status:
RECRUITING
Last Update Posted:
2025-09-09
First Post:
2018-09-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Sponsor:
M.D. Anderson Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Acute Bilineal Leukemia | View |
| None | Acute Biphenotypic Leukemia | View |
| None | Chronic Myelomonocytic Leukemia | View |
| None | IDH2 Gene Mutation | View |
| None | Myelodysplastic Syndrome | View |
| None | Recurrent Acute Myeloid Leukemia | View |
| None | Refractory Acute Myeloid Leukemia | View |
Keywords: